{
    "clinical_study": {
        "@rank": "156420", 
        "arm_group": {
            "arm_group_label": "Defactinib", 
            "arm_group_type": "Experimental", 
            "description": "Oral defactinib (VS-6063) administered BID during a 21 day cycle."
        }, 
        "brief_summary": {
            "textblock": "This is a phase I, open-label, dose-escalation trial of defactinib (VS-6063), a focal\n      adhesion kinase inhibitor, in Japanese patients with non-hematologic malignancies.  The\n      purpose of this study is to assess the safety (including the recommended phase 2 dose), the\n      pharmacokinetics, and the anti-cancer activity of defactinib (VS-6063)."
        }, 
        "brief_title": "Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies", 
        "condition": "Non Hematologic Cancers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able to provide signed and dated informed consent prior to initiation of any study\n             procedures.\n\n          -  Age \u2265 20 years.\n\n          -  Subject must be of Japanese descent.\n\n          -  Subjects must have a histopathologically confirmed diagnosis of a non-hematologic\n             malignancy.\n\n          -  Subjects must have no further standard of care options or have refused standard\n             therapy.\n\n          -  All persistent clinically significant toxicities from prior chemotherapy must be \u2264\n             Grade 1.\n\n          -  ECOG performance status of 0 or 1, measured within 72 hours before the start of\n             treatment.\n\n          -  Predicted life expectancy of \u2265 3 months.\n\n          -  Adequate renal function [creatinine \u2264 1.5x ULN (upper limit of normal)] or GFR of \u2265\n             50mL/min.\n\n          -  Adequate hepatic function (total bilirubin \u2264 1.5x ULN for the institution; AST\n             [aspartate transaminase] and ALT [alanine transaminase] \u2264 3x ULN, or \u2264 5x ULN if due\n             to liver involvement by tumor).\n\n          -  Adequate bone marrow function (hemoglobin \u2265 9.0 g/dL; platelets \u2265 100 x109 cells/L;\n             absolute neutrophil count \u2265 1.5x109 cells/L).\n\n          -  Corrected QT interval (QTc) < 470 ms (as calculated by the Fridericia correction\n             formula).\n\n          -  Negative pregnancy test for women of child-bearing potential. (A woman of\n             childbearing potential is defined as one who is biologically capable of becoming\n             pregnant except for  women who have undergone permanent contraceptive surgery or are\n             postmenopausal (defined as the absence of menstruation for at least 12 months without\n             other medical reasons).\n\n          -  Men and women of child bearing potential must agree to use adequate birth control\n             throughout their participation in the study and for 90 days following the last study\n             treatment.\n\n          -  Willing and able to participate in the trial and comply with all trial requirements.\n\n        Exclusion Criteria:\n\n          -  Gastrointestinal (GI) condition which could interfere with the swallowing or\n             absorption of study medication.\n\n          -  Uncontrolled or severe concurrent medical condition (including uncontrolled brain\n             metastases).  Stable brain metastases either treated or being treated with a stable\n             dose of steroids/ anticonvulsants, with no dose change within 28 days prior to the\n             first dose of study drug, will be allowed.\n\n          -  History of upper gastrointestinal bleeding, ulceration, or perforation within 12\n             months prior to the first dose of study drug.\n\n          -  Known history of stroke or cerebrovascular accident within 6 months prior to the\n             first dose of study drug.\n\n          -  Subjects with known infection with human immunodeficiency virus (HIV) or Acquired\n             Immune Deficiency Syndrome (AIDS) (testing not required).\n\n          -  Subjects with known Hepatitis B or C (Including known seropositivity Hepatitis B\n             virus surface antigen (HBsAg), hepatitis C virus antibody (HCV antibody).\n\n          -  Subjects being actively treated for a secondary malignancy.\n\n          -  Cancer-directed therapy (chemotherapy, radiotherapy, hormonal therapy, biologic or\n             immunotherapy, etc.) within 28 days of the first dose of study drug or 5 half-lives,\n             whichever is shorter.\n\n          -  Major surgery within 28 days prior to the first dose of study drug.\n\n          -  Use of an investigational drug within 28 days or 5 half-lives (whichever is shorter)\n             prior to the first dose of study drug.  A minimum of 10 days between termination of\n             the investigational drug and administration of the study treatment is required. In\n             addition, any drug-related toxicity except alopecia should have recovered to grade 1\n             or less.\n\n          -  Women who are pregnant or breastfeeding.\n\n          -  Any evidence of serious active infections.\n\n          -  Uncontrolled or severe cardiovascular disease, including myocardial infarct or\n             unstable angina within 6 months prior to study treatment, New York Heart Association\n             (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring\n             medication for treatment, clinically significant pericardial disease, or cardiac\n             amyloidosis.\n\n          -  Known history of malignant hypertension\n\n          -  Uncontrolled intercurrent illness including symptomatic congestive heart failure,\n             cardiac arrhythmia, or psychiatric illness/social situations that would limit\n             compliance with study requirements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01943292", 
            "org_study_id": "VS-6063-102"
        }, 
        "intervention": {
            "arm_group_label": "Defactinib", 
            "intervention_name": "Defactinib", 
            "intervention_type": "Drug", 
            "other_name": "VS-6063"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Focal Adhesion Kinase inhibitor", 
            "FAK inhibitor", 
            "Cancer Stem Cells", 
            "CSC"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Osaka", 
                    "country": "Japan"
                }, 
                "name": "Kinki University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of VS-6063, a Focal Adhesion Kinase Inhibitor, in Japanese Subjects With Non-Hematologic Malignancies", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Japan: Ministry of Health, Labor and Welfare"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adverse events and their frequency, duration and severity, physical examination, laboratory parameters, vital signs and ECG change monitoring as determined based on CTCAE (Common Toxicity Criteria for Adverse Effects) 4.03", 
            "measure": "Assess the safety and tolerability of defactinib (VS-6063) in Japanese subjects with non-hematologic malignancies", 
            "safety_issue": "Yes", 
            "time_frame": "From start of treatment to end of treatment, an expected average of 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01943292"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The RP2D will be determined based on the MTD of defactinib (VS-6063) as determined by number of participants with dose limiting toxicities (DLTs) related to defactinib.", 
                "measure": "Define the maximum tolerated dose (MTD), if achieved, and establish the recommended phase 2 dose (RP2D) of defactinib (VS-6063) in Japanese subjects.", 
                "safety_issue": "Yes", 
                "time_frame": "From start of treatment to end of cycle 1 (21 day cycles)"
            }, 
            {
                "description": "PK parameters, including but not limited to plasma concentration, AUC (Area Under Curve) 0-t, Cmax, Tmax, and T1/2. Total 24-hour urine output will be collected in conjunction with PK sampling to assess the elimination of defactinib (VS-6063) and its potential metabolites.", 
                "measure": "Assess the pharmacokinetics, metabolism and elimination of defactinib (VS-6063) in plasma and urine.", 
                "safety_issue": "No", 
                "time_frame": "Time points at Day 1 and Day 15 in Cycle 1"
            }, 
            {
                "description": "Response rate and progression-free survival, as determined by Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1", 
                "measure": "Evaluate the efficacy (response rate and progression-free survival) of subjects treated with defactinib (VS-6063).", 
                "safety_issue": "No", 
                "time_frame": "Every 8 weeks up to end of treatment, an expected average of 12 weeks"
            }
        ], 
        "source": "Verastem, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Verastem, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}